Drug Resistance
Sep 22, 2016
Sygnis AG and ECACC Collaboration; BioNTech and Genentech Partnership; Partnership between Zydus Cadila and Takeda; Global Agreement between Regeneron Pharmaceuticals, Inc. and Teva Pharmaceutical
Collaboration between Sygnis AG and ECACC for licensing and distribution of Caco-2 cell line Sygnis AG enters into a collaboration agreement with ECACC to significantly expand Sygnis' Caco-2 business. Under the collaboration, ECACC will organize that companies obtain the license for the use of the Caco-2 cell line f...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
